Literature DB >> 11437690

Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.

C Richard-Miceli1, M Dougados.   

Abstract

Tumour necrosis factor (TNF)-alpha has been found to play a central role in the pathogenesis of rheumatoid arthritis, leading to development of novel drug therapies that neutralise the deleterious effects of this cytokine. This new concept of immunobiological treatment of rheumatoid arthritis has yielded successful results. Although the 2 currently available TNFalpha blockers, infliximab and etanercept, differ in structure, mechanism of action and pharmacokinetics, they have provided similar benefits both in clinical improvement and in slowing and even arresting the progression of radiographic damage. This therapeutic response seems to be unequalled by "conventional" treatments in rheumatoid arthritis, and is incontestably a turning point in the therapeutic management of this disease.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11437690     DOI： 10.2165/00063030-200115040-00005

Source DB:  PubMed          Journal:  BioDrugs        ISSN： 1173-8804            Impact factor:   5.807


  9 in total

1.  Editorial: cytokine inhibition for treatment of Alzheimer's disease.

Authors:  Paul B Rosenberg
Journal:  MedGenMed       Date:  2006-04-26

2.  Elevated levels of tumor necrosis factor alpha (TNF-alpha) in human immunodeficiency virus type 1-transgenic mice: prevention of death by antibody to TNF-alpha.

Authors:  Swapan K De; Krishnakumar Devadas; Abner Louis Notkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species.

Authors:  Darren C Phillips; Kevin J Woollard; Helen R Griffiths
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 4.  Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF.

Authors:  S Ehlers
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

5.  The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Authors:  Marina Stolina; Brad Bolon; Scot Middleton; Denise Dwyer; Heather Brown; Diane Duryea; Li Zhu; Alison Rohner; James Pretorius; Paul Kostenuik; Ulrich Feige; Debra Zack
Journal:  J Clin Immunol       Date:  2008-08-26       Impact factor: 8.317

6.  Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis.

Authors:  Chrystal M Paulos; Bindu Varghese; William R Widmer; Gert J Breur; Erina Vlashi; Philip S Low
Journal:  Arthritis Res Ther       Date:  2006-04-28       Impact factor: 5.156

7.  Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.

Authors:  Hiroki Wakabayashi; Hitoshi Inada; Yosuke Nishioka; Masahiro Hasegawa; Kusuki Nishioka; Akihiro Sudo
Journal:  Drugs R D       Date:  2017-03

8.  RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Authors:  Marina Stolina; Georg Schett; Denise Dwyer; Steven Vonderfecht; Scot Middleton; Diane Duryea; Efrain Pacheco; Gwyneth Van; Brad Bolon; Ulrich Feige; Debra Zack; Paul Kostenuik
Journal:  Arthritis Res Ther       Date:  2009-12-11       Impact factor: 5.156

9.  Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Francesca Minonzio; Paola Bonara; Andrea Doria; Mario Carrabba
Journal:  Arthritis Res Ther       Date:  2005-01-10       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.